Vaxart (VXRT) Fireside chat summary

Introduction and agenda

• Management recapped key developments, including partnership progress, cost management, and clinical trial priorities as the company moves into 2026.

• The session included a Q&A with stockholders, covering operational, financial, and strategic topics.

Background and experience of the speaker

• The fireside chat featured the CEO, Chief Scientific Officer, Chief Medical Officer, CFO, and General Counsel, each addressing questions in their respective domains.

Current industry trends

• The vaccine funding environment remains in flux domestically, with increased scrutiny on mRNA vaccines and shifting public sentiment.

• Global demand for effective, thermostable, and easy-to-administer vaccines is rising, with major international commitments for immunization funding through 2030.